Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
Goglia AG, Alshalalfa M, Khan A, Isakov DR, Hougen HY, Swami N, Kannikal J, Mcbride SM, Gomez DR, Punnen S, Nguyen PL, Iyengar P, Antonarakis ES, Mahal BA, Dee EC.
Goglia AG, et al. Among authors: dee ec.
J Natl Cancer Inst. 2024 Sep 10:djae224. doi: 10.1093/jnci/djae224. Online ahead of print.
J Natl Cancer Inst. 2024.
PMID: 39254651